Neoadjuvant chemotherapy for extremity osteosarcoma

Preliminary results of the Rizzoli's 4th study

Gaetano Bacci, Stefano Ferrari, Mario Mercuri, Alessandra Longhi, Rodolfo Capanna, Amelia Tienghi, Adalberto Brach Del Prever, Alessandro Comandone, Marilena Cesari, Gabriella Bernini, Piero Picci

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

A neoadjuvant chemotherapy protocol (1/93-1/95) for extremity osteosarcoma preoperatively using high-dose methotrexate (HDMTX) as single agent per cycle and three different combinations of other drugs (CDP/IFO,CDP/ADM,IFO/ADM) is reported. The four drugs were used postoperatively as single agents. Treatment was uniform, but suspended earlier if total necrosis was attained. An improvement was found in the results of the previous study using only IFO postoperatively, with 16/119 patients (97%) avoiding amputation, and 38 (32%) attaining complete necrosis. At a 3-year (2-4 years) mean follow-up, 92 patients (76%) remained continuously disease-free, 2 died of chemotherapy-related toxicity and 25 suffered relapse. Projected 3-year DFS also improved (75% vs. 600%; p = 0.04). Despite limb salvage, local recurrences (6.3%) and infections were few, although postoperative chemotherapy was restarted within a week. Therefore, until new effective drugs are found, expertise in using the four known drugs may improve cure rate and help to avoid amputation in almost all patients.

Original languageEnglish
Pages (from-to)41-48
Number of pages8
JournalActa Oncologica
Volume37
Issue number1
DOIs
Publication statusPublished - 1998

Fingerprint

Cytidine Diphosphate
Osteosarcoma
Extremities
Amputation
Drug Therapy
Necrosis
Pharmaceutical Preparations
Recurrence
Limb Salvage
Drug Combinations
Methotrexate
Infection
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Neoadjuvant chemotherapy for extremity osteosarcoma : Preliminary results of the Rizzoli's 4th study. / Bacci, Gaetano; Ferrari, Stefano; Mercuri, Mario; Longhi, Alessandra; Capanna, Rodolfo; Tienghi, Amelia; Brach Del Prever, Adalberto; Comandone, Alessandro; Cesari, Marilena; Bernini, Gabriella; Picci, Piero.

In: Acta Oncologica, Vol. 37, No. 1, 1998, p. 41-48.

Research output: Contribution to journalArticle

Bacci, G, Ferrari, S, Mercuri, M, Longhi, A, Capanna, R, Tienghi, A, Brach Del Prever, A, Comandone, A, Cesari, M, Bernini, G & Picci, P 1998, 'Neoadjuvant chemotherapy for extremity osteosarcoma: Preliminary results of the Rizzoli's 4th study', Acta Oncologica, vol. 37, no. 1, pp. 41-48. https://doi.org/10.1080/028418698423168
Bacci, Gaetano ; Ferrari, Stefano ; Mercuri, Mario ; Longhi, Alessandra ; Capanna, Rodolfo ; Tienghi, Amelia ; Brach Del Prever, Adalberto ; Comandone, Alessandro ; Cesari, Marilena ; Bernini, Gabriella ; Picci, Piero. / Neoadjuvant chemotherapy for extremity osteosarcoma : Preliminary results of the Rizzoli's 4th study. In: Acta Oncologica. 1998 ; Vol. 37, No. 1. pp. 41-48.
@article{1d63ec5fbb694a798505b691c378e4e8,
title = "Neoadjuvant chemotherapy for extremity osteosarcoma: Preliminary results of the Rizzoli's 4th study",
abstract = "A neoadjuvant chemotherapy protocol (1/93-1/95) for extremity osteosarcoma preoperatively using high-dose methotrexate (HDMTX) as single agent per cycle and three different combinations of other drugs (CDP/IFO,CDP/ADM,IFO/ADM) is reported. The four drugs were used postoperatively as single agents. Treatment was uniform, but suspended earlier if total necrosis was attained. An improvement was found in the results of the previous study using only IFO postoperatively, with 16/119 patients (97{\%}) avoiding amputation, and 38 (32{\%}) attaining complete necrosis. At a 3-year (2-4 years) mean follow-up, 92 patients (76{\%}) remained continuously disease-free, 2 died of chemotherapy-related toxicity and 25 suffered relapse. Projected 3-year DFS also improved (75{\%} vs. 600{\%}; p = 0.04). Despite limb salvage, local recurrences (6.3{\%}) and infections were few, although postoperative chemotherapy was restarted within a week. Therefore, until new effective drugs are found, expertise in using the four known drugs may improve cure rate and help to avoid amputation in almost all patients.",
author = "Gaetano Bacci and Stefano Ferrari and Mario Mercuri and Alessandra Longhi and Rodolfo Capanna and Amelia Tienghi and {Brach Del Prever}, Adalberto and Alessandro Comandone and Marilena Cesari and Gabriella Bernini and Piero Picci",
year = "1998",
doi = "10.1080/028418698423168",
language = "English",
volume = "37",
pages = "41--48",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy for extremity osteosarcoma

T2 - Preliminary results of the Rizzoli's 4th study

AU - Bacci, Gaetano

AU - Ferrari, Stefano

AU - Mercuri, Mario

AU - Longhi, Alessandra

AU - Capanna, Rodolfo

AU - Tienghi, Amelia

AU - Brach Del Prever, Adalberto

AU - Comandone, Alessandro

AU - Cesari, Marilena

AU - Bernini, Gabriella

AU - Picci, Piero

PY - 1998

Y1 - 1998

N2 - A neoadjuvant chemotherapy protocol (1/93-1/95) for extremity osteosarcoma preoperatively using high-dose methotrexate (HDMTX) as single agent per cycle and three different combinations of other drugs (CDP/IFO,CDP/ADM,IFO/ADM) is reported. The four drugs were used postoperatively as single agents. Treatment was uniform, but suspended earlier if total necrosis was attained. An improvement was found in the results of the previous study using only IFO postoperatively, with 16/119 patients (97%) avoiding amputation, and 38 (32%) attaining complete necrosis. At a 3-year (2-4 years) mean follow-up, 92 patients (76%) remained continuously disease-free, 2 died of chemotherapy-related toxicity and 25 suffered relapse. Projected 3-year DFS also improved (75% vs. 600%; p = 0.04). Despite limb salvage, local recurrences (6.3%) and infections were few, although postoperative chemotherapy was restarted within a week. Therefore, until new effective drugs are found, expertise in using the four known drugs may improve cure rate and help to avoid amputation in almost all patients.

AB - A neoadjuvant chemotherapy protocol (1/93-1/95) for extremity osteosarcoma preoperatively using high-dose methotrexate (HDMTX) as single agent per cycle and three different combinations of other drugs (CDP/IFO,CDP/ADM,IFO/ADM) is reported. The four drugs were used postoperatively as single agents. Treatment was uniform, but suspended earlier if total necrosis was attained. An improvement was found in the results of the previous study using only IFO postoperatively, with 16/119 patients (97%) avoiding amputation, and 38 (32%) attaining complete necrosis. At a 3-year (2-4 years) mean follow-up, 92 patients (76%) remained continuously disease-free, 2 died of chemotherapy-related toxicity and 25 suffered relapse. Projected 3-year DFS also improved (75% vs. 600%; p = 0.04). Despite limb salvage, local recurrences (6.3%) and infections were few, although postoperative chemotherapy was restarted within a week. Therefore, until new effective drugs are found, expertise in using the four known drugs may improve cure rate and help to avoid amputation in almost all patients.

UR - http://www.scopus.com/inward/record.url?scp=7144223427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7144223427&partnerID=8YFLogxK

U2 - 10.1080/028418698423168

DO - 10.1080/028418698423168

M3 - Article

VL - 37

SP - 41

EP - 48

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 1

ER -